Saturday 17 October 2026
Export ZYME’s income statement to Excel — free account
Zymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.
25.07
0.68
−2.64%
Follow ZYME
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
9.62 | 18.74 | 23.01 | 51.39 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(41.20) | (193.53) | (40.90) | (59.72) | |
P/B ratio |
4.04 | 7.39 | 11.43 | 23.74 | |
Price to Tangible BV |
4.22 | 7.78 | 12.43 | 28.33 | |
EV/Sales |
7.92 | 16.58 | 18.52 | 44.11 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(16.57) | (53.23) | (19.99) | (13.72) | |
EV/FCF |
(16.08) | (49.69) | (19.33) | (13.49) | |
Quick Ratio |
6.69 | 5.52 | 10.36 | 5.86 | |
Current Ratio |
6.94 | 5.88 | 10.82 | 6.32 | |
Net Debt/EBITDA |
12.90 | 5.42 | 8.24 | 6.74 | |
Debt/Assets |
0.00% | 0.08% | 0.06% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.30 | 0.26 | 0.18 | 0.09 | |
Operating CF/Net income |
1.60 | 0.25 | 1.04 | 0.71 | |
Capex/Depreciation |
(0.16) | (0.36) | (0.08) | 0.00 | |
Interest Coverage |
— | — | (22.81) | (6.40) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
51.23% | 613.60% | 625.79% | 421.24% | |
Intangible Assets out of Total Assets |
0.03 | 0.04 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
25.03% | 351.89% | 288.00% | 246.93% | |
Graham Net Nets |
0.17 | 0.09 | 0.04 | (0.01) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.92%) | (4.10%) | (5.47%) | (7.73%) | |
Free Cash Flow Yield |
(5.12%) | (1.78%) | (4.16%) | (6.36%) | |
Revenue per Share |
0.36 | 0.03 | 0.03 | 0.06 | |
Operating CF per Share |
(0.41) | (0.14) | (0.61) | (0.44) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.42) | (0.15) | (0.62) | (0.44) | |
Cash per Share |
3.33 | 3.03 | 4.88 | 3.71 | |
Shareholders Equity per Share |
4.22 | 3.56 | 2.19 | 1.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.22 | 3.56 | 2.19 | 1.10 | |
Free Cash Flow |
(31.82) | (10.98) | (45.93) | (31.95) | |
Working Capital |
249.67 | 206.45 | 350.03 | 251.15 | |
Capital Expenditures |
(0.41) | (0.72) | (0.22) | 0.00 | |
Net Current Asset Value |
214.51 | 170.74 | 71.05 | (18.21) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.29 | 0.09 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
26.53 | 30.23 | 14.63 | 4.28 | |
Average Payables |
43.07 | 48.09 | 34.22 | 29.23 | |
Average Assets |
442.21 | 404.81 | 451.87 | 402.67 | |
Average Common Equity |
343.52 | 303.63 | 244.28 | 207.44 |
Columns are period end dates